If this message does not display properly, please click here to launch your browser.
|
Based on our Pharmacor advisory services entitled Methicillin-Resistant Staphylococcus aureus (MRSA) and Community-Acquired Pneumonia, Decision Resources is offering an exclusive Pharmacor analyst call entitled Ceftobiprole’s Non-Approval in the U.S. Changes the Forecast for MRSA and Community-Acquired Pneumonia – Who Will Get the Projected $150 Million? Because this presentation will feature major updates, it is ONLY available to purchasers of one or both of these Pharmacor advisory services. Please contact us to learn how you can purchase one or both of these Pharmacor advisory services and attend the analyst call. The recently-announced rejection by the U.S. Food and Drug Administration (FDA) of Johnson & Johnson/Basilea’s application to market ceftobiprole for the treatment of complicated skin and skin structure infections will create a significant void in the MRSA pipeline. As a result of the FDA’s action, Decision Resources has updated its Pharmacor Methicillin-Resistant Staphylococcus aureus (MRSA) and Community-Acquired Pneumonia advisory services. Ceftobiprole, which was widely considered to be a highly promising drug candidate, had been previously forecasted by Decision Resources to garner more than $150 million in peak year sales for the treatment of MRSA and community-acquired pneumonia in the world’s major pharmaceutical markets. This 15-minute analyst call, presented by Director of Infectious Diseases Danielle Drayton, Ph.D., will answer the following questions:
Dr. Drayton will conduct a live Q & A session after the presentation. Registration Ceftobiprole’s Non-Approval in the U.S. Changes the Forecast for MRSA and Community-Acquired Pneumonia – Who Will Get the Projected $150 Million? January 14, 2010 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris). To learn how you can purchase one or both of these Pharmacor advisory services and attend the analyst call, please contact us using the information below. In North America — Keith Rourke at 781-296-2656 or krourke@dresources.com |
|
||||
Terms of Use | Privacy Policy | Contact Us | Careers |
|||||
Danielle Drayton, Ph.D. is the Director of Infectious Diseases at Decision Resources. Prior to joining the company, she completed a postdoctoral fellowship at CBR Institute for Biomedical Research (Harvard Medical School), where she investigated a novel role of natural killer cells in adaptive immunity. She has conducted extensive research on the mechanisms of tumor necrosis factor- and lymphotoxin-mediated lymphoid organ development, inflammation, and angiogenesis and has coauthored numerous peer-reviewed research articles in these areas. Dr. Drayton holds a Ph.D. in immunobiology from Yale University and a B.S. in microbiology and immunology from the University of Miami, Florida.